NICE has added Nano‑X Imaging Ltd.’s HealthVCF and HealthOST bone‑analysis solutions to its Early Value Assessment programme, authorising their use in NHS hospitals for a three‑year period. The endorsement follows the company’s EU MDR CE‑mark for HealthOST, which was granted on June 5 2025, and positions the AI tools as a validated, low‑radiation option for opportunistic vertebral fragility fracture detection in routine CT scans.
The decision expands Nano‑X’s commercial reach into the UK’s largest public‑health system. By allowing NHS hospitals to deploy the software without additional imaging, the company can accelerate adoption of its AI analytics, potentially increasing revenue from the UK market and strengthening its end‑to‑end diagnostic ecosystem. The endorsement also signals regulatory confidence in the clinical value of the technology, a key catalyst for future reimbursement and market penetration in other European countries.
Financially, Nano‑X reported 2024 revenue of $11.28 million, up 13.9% from $9.91 million in 2023, while sustaining a net loss of $53.52 million. In Q3 2025, the company generated $3.4 million in revenue versus $3.0 million in Q3 2024, reflecting steady demand in its AI solutions division. Despite revenue growth, operating and net margins remain negative, underscoring the company’s ongoing investment in product development and market expansion.
Investors reacted strongly to the endorsement, citing the opening of the NHS market, the company’s raised 2026 revenue outlook, and its expanding AI partnership network, including a reseller agreement with 3DR Labs that will extend reach to over 1,800 North American sites. The endorsement is viewed as a pivotal step toward broader commercial traction and increased revenue visibility for Nano‑X’s AI platform.
CEO Erez Meltzer said the NICE recommendation “provides clear initial validation of the benefit that our AI bone solutions can provide in detection of vertebral fragility fractures.” He added that Nano‑X will work closely with NHS partners to generate evidence and expand usage beyond the initial three‑year assessment period, reinforcing the company’s commitment to scaling its AI diagnostics in high‑impact healthcare settings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.